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ABSTRACT
In pre-mRNA splicing, a conserved AG/G at the
30-splice site is recognized by U2AF
35. A disease-
causing mutation abrogating the G nucleotide at
the first position of an exon (E
+1) causes exon
skipping in GH1, FECH and EYA1, but not in LPL or
HEXA. Knockdown of U2AF
35 enhanced exon
skipping in GH1 and FECH. RNA-EMSA revealed
that wild-type FECH requires U2AF
35 but wild-type
LPL does not. A series of artificial mutations in the
polypyrimidine tracts of GH1, FECH, EYA1, LPL and
HEXA disclosed that a stretch of at least 10–15 pyr-
imidines is required to ensure normal splicing in the
presence of a mutation at E
+1. Analysis of nine other
disease-causing mutations at E
+1 detected five
splicing mutations. Our studies suggest that a
mutation at the AG-dependent 30-splice site that
requires U2AF
35 for spliceosome assembly causes
exon skipping, whereas one at the AG-independent
30-splice site that does not require U2AF
35 gives rise
to normal splicing. The AG-dependence of the
30-splice site that we analyzed in disease-causing
mutations at E
+1 potentially helps identify yet unrec-
ognized splicing mutations at E
+1.
INTRODUCTION
In higher eukaryotes, generation of functional mRNA is
dependent on the removal of introns from pre-mRNA by
splicing (1). The splicing process occurs in the
spliceosome, the major components of which include ﬁve
small nuclear RNAs and their associated proteins (U1,
U2, U4, U5 and U6 snRNPs) in addition to a large
number of non-snRNP proteins (2). In the ﬁrst step of
assembly of the spliceosome, U1 snRNP, SF1, U2AF
65
and U2AF
35 bind to the splicing cis-elements at the 50
splice site (ss), the branch point sequence (BPS), the
polypyrimidine tract (PPT) and the acceptor site, respect-
ively, to form complex E (3).
Yeast has a well conserved BPS of UACUAAC (4),
whereas we recently reported that human carries a
highly degenerate BPS of yUnAy, where ‘y’ and ‘n’ repre-
sent pyrimidines and any nucleotides, respectively (5).
Degeneracy of the human BPS supports a notion that
the human BPS is likely to be recognized along with the
downstream PPT where U2AF
65 binds and possibly with
the invariant AG dinucleotide at the 30 ss where U2AF
35
binds (6,7). U2AF
65 and U2AF
35 also make a heterodimer
(8). In PPT, uridines are preferred over cytidines (9,10). In
addition, PPT with 11 continuous uridines is highly com-
petent and the position of such PPT is not critical (10). On
the other hand, PPTs with only ﬁve or six uridines are
required to be located close the 30 AG for efﬁcient
splicing. In addition, phosphorylated DEK binds to and
cooperates with U2AF
35 for proper recognition of the 30 ss
(11).
In the next step of the spliceosome assembly, the bound
U2AF
65 and U2AF
35 facilitate substitution of SF1 for
U2snRNP at the branch point to form complex A.
Introns carrying a long stretch of PPT do not require
U2AF
35 for this substitution, which is called
‘AG-independent 30 ss’ (12–15). On the other hand,
introns with a short or degenerate PPT require both
U2AF
65 and U2AF
35 for this substitution, which is
called ‘AG-dependent 30 ss’. Thereafter, the U4/U6.U5
tri-snRNP is integrated into the spliceosome to form
complex B and the initial assembly of the spliceosome is
completed.
The invariant AG dinucleotides are frequently reported
targets of mutations causing human diseases, and the most
frequent consequence is skipping of one or more exons
(16). In addition, even mutations in highly degenerate
BPS (5) and PPT (17) give rise to aberrant splicing
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also affect the ﬁrst nucleotide of an exon (E
+1), but their
effects on pre-mRNA splicing have been rarely
scrutinized. As far as we know, only three such mutations
in FECH (19), GH1 (20) and EYA1 (21) have been
reported to cause aberrant splicing. Similarly, two such
mutations in LPL (22) and HEXA (23) have been
reported to have no effect on splicing. In this communi-
cation, we dissected molecular bases that differentiate
splicing-disrupting and splicing-competent mutations,
and found that AG-dependent ss is vulnerable to a
mutation at E
+1, whereas AG-independent ss is tolerant.
MATERIALS AND METHODS
Minigene constructs and mutagenesis
Human genes of our interest were PCR-ampliﬁed from
HEK293 cells using the KOD plus DNA polymerase
(Toyobo). We introduced restriction enzyme-recognition
sites at the 50-end of the forward and reverse primers. We
inserted the amplicon into the pcDNA3.1(+) mammalian
expression vector (Invitrogen). We introduced patients’ or
artiﬁcial mutations with the QuikChange site-directed mu-
tagenesis kit (Stratagene). We conﬁrmed the absence of
unexpected artifacts with the CEQ8000 genetic analyzer
(Beckman Coulter).
Cell culture and transfection procedures
HEK293 cells were maintained in the Dulbecco’s
minimum essential medium (DMEM, Sigma-Aldrich)
with 10% fetal bovine serum (FBS, Sigma-Aldrich). At
 50% conﬂuency ( 5 10
5 cells) in a 12-well plate, 1ml
of fresh Opti-MEM I (Invitrogen) was substituted for
DMEM, and 500ng of a minigene with 1.5ml of the
FuGENE6 transfection reagent (Roche Diagnostics)
were then added. After 4h, 2ml of DMEM with 10%
FBS was overlaid, and the cells were incubated overnight.
The transfection medium was replaced with 2ml of fresh
DMEM with 10% FBS. RNA was extracted at 48h after
initiation of transfection.
RNA extraction and RT–PCR
Total RNA from HEK293 was extracted by Trizol reagent
(Invitrogen) according to the manufacturer’s protocols.
The quantity and quality of RNA was determined by spec-
trophotometry (NanoDrop Techonologies). Twenty
percent of the isolated RNA was used as a template for
cDNA synthesis with the Oligo(dT) 12–18 Primer
(Invitrogen) and the ReverTra Ace (Toyobo). Ten
percent of the synthesized cDNA was used as a template
for RT–PCR ampliﬁcation with T7 primer (50-TAATACG
ACTCACTATAGGG-30) and gene-speciﬁc primers for
minigenes in pcDNA3.1(+). Image J software (National
Institutes of Health) was used to quantify intensities of
fragments. We employed JMP (SAS Institute) for statis-
tical analysis.
RNA interference to knockdown U2AF
35
We synthesized siRNA of 50-GGCUGUGAUUGACUU
GAAUdTdT-30 (GenBank accession number
NM_006758, nucleotides 459–479), which is against the
shared sequence of U2AF
35a and U2AF
35b (15). We
employed Lipofectamine 2000 (Invitrogen) to cotransfect
plasmids and siRNAs according to the manufacturer’s
protocols. Brieﬂy, the transfection reagent included
300ng of the plasmid, 50pmol of siRNA, and 2mlo f
lipofectamine 2000 in 100ml of Opti-MEM I. The cells
were harvested by western blotting for 48h after transfec-
tion. The primary antibodies were goat polyclonal
antibody for U2AF
35 (Santa Cruz Biotechnology), and
mouse monoclonal antibodies for U2AF
65 (Santa Cruz
Biotechnology) and PTB (Zymed Laboratories). The sec-
ondary antibodies were HRP-conjugated mouse anti-goat
(Santa Cruz Biotechnology) or sheep anti-mouse (GE
healthcare) antibodies. The immunoreactive proteins
were detected by enhanced chemiluminescence (ECL,
Amersham Biosciences).
For the siRNA rescue assay, we cloned the human
U2AF
35 cDNA (Open Biosystems) into the HindIII and
EcoRI restriction sites of the p3XFLAG-CMV-14 vector
(Sigma-Aldrich). We introduced four silent mutations into
the siRNA target region using the QuikChange
site-directed mutagenesis kit with a primer, 50-GAAAAG
GCTGTAATCGATTTAAATAACCGTTGGTT-30,
where artiﬁcial mutations are underlined (24).
RNA probe synthesis
We synthesized [a-
32P]-CTP-labeled RNA using the
Riboprobe in vitro transcription system (Promega) from
a PCR-ampliﬁed fragment according to the manufactur-
er’s instructions. We used the same forward primer for all
the probes with the sequence of 50-TAATACGACTCACT
ATAGGGAGACAGG-30, where the italicized is T7
promoter and the underlined is for annealing to the
reverse primer. The four reverse primers were: wild-type
FECH,5 0-TGGACCAACCTATGCGAAAGATAGACG
AATGCGTAAGCCTGTCTC-30; mutant FECH, 50-TGG
ACCAAACTATGCGAAAGATAGACGAATGCGTA
AGCCTGTCTC-30; wild-type LPL, 50-TGGATCGAGG
CCTTAAAAGGGAAAAAAGCAGGAACACCCTGT
CTC-30; and mutant LPL, 50-TGGATCGAGGACTTAA
AAGGGAAAAAAGCAGGAACACCCTGTCTC-30,
where the underlined is for annealing to the forward
primer.
Expression and puriﬁcation of recombinant proteins
The human U2AF
35 and U2AF
65 cDNAs were obtained
from Open Biosystems. U2AF
35 and U2AF
65 cDNAs
were subcloned into the BamHI and EcoRI restriction
sites of the pFastBac HTb vector. The recombinant
baculoviruses were expressed using the Bac-to-Bac
Baculovirus Expression System (Invitrogen) according to
the manufacturer’s instructions. Infected Sf9 cells were
harvested after 48h and resuspended in the lysis buf-
fer containing 50mM sodium phosphate, 10mM
imidazole, 300mM NaCl, 1% Triton X-100, 2mM
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Cocktail (Roche Applied Science) and 5U endonuclease
in pH 7.0. His-tagged U2AF
35 and U2AF
65 proteins were
puriﬁed using the TALON metal afﬁnity resins (Clontech)
under the denatured and native conditions, respectively.
Puriﬁed U2AF
35 was refolded by extended dialysis in
dialysis buffer (50mM sodium phosphate, 300mM
NaCl, 150mM imidazole, pH 7.0). We determined the
protein concentrations using the Pierce 660nm Protein
Assay Reagent (Thermo Scientiﬁc).
RNA-electrophoretic mobility shift assay
The radioactively labeled RNA (1 10
5 cpm) was
incubated at room temperature with varying concentra-
tions of recombinant proteins, 16mg of yeast tRNA, and
1.6 U of RNasin (Toyobo) in a ﬁnal volume of 20ml of the
binding buffer (20mM HEPES pH 7.8, 50mM KCl, 3mM
MgCl2, 0.5mM dithiothreitol, 0.5mM EDTA and 5%
glycerol). After 20min, the RNA–protein complexes
were separated on 5% non-denaturing polyacrylamide
gels in 1 TBE buffer at 4 C. The gels were dried and
complex formation was visualized using the Typhoon
8600 Imager (GE Healthcare).
In silico analysis of the human genome and ESE-motifs
We analyzed human genome annotations (NCBI Build
37.1, hg19) by writing Perl programs, and executing
them either on the PrimePower HPC2500/Solaris 9 super-
computer (Fujitsu) or on the cygwin UNIX emulator
running on a Windows computer. To search for
ESE-motifs, we used the ESE Finder (http://rulai.cshl
.org/ESE/) (25,26), the RESUCE-ESE server (http://
genes.mit.edu/burgelab/rescue-ese/) (27), the FAS-ESS
server (http://genes.mit.edu/fas-ess/) (28), the PESX
server (http://cubweb.biology.columbia.edu/pesx/)
(29,30), and the ESRsearch server (http://ast.bioinfo.tau
.ac.il/) (31).
RESULTS
Recapitulation of normal and aberrant splicing in
minigenes
We ﬁrst constructed minigenes of GH1, FECH, EYA1,
LPL and HEXA, and introduced a previously reported
disease-causing mutation at E
+1 (Figure 1A). These
minigenes successfully recapitulated normal and aberrant
splicings: mutations in GH1, FECH and EYA1 caused
exon skipping, whereas those in LPL or HEXA did not
(Figure 1B).
Down-regulation of U2AF
35 increased exon skipping in
wild-type GH1 and FECH, but not in wild-type EYA1,
LPL and HEXA
We predicted that a mutation at E
+1 should disrupt
binding of U2AF
35. We thus hypothesized that GH1,
FECH and EYA1 require binding of U2AF
35 for the
assembly of spliceosome, whereas LPL and HEXA do
not require it. To prove this hypothesis, we ﬁrst knocked
down U2AF
35 and analyzed its effect on the wild-type
minigenes. We achieved an efﬁcient down-regulation of
U2AF
35 in HEK293 cells (Figure 2A). We also conﬁrmed
A
B
Figure 1. Recapitulation of normal and aberrant splicing of ﬁve genes. (A) Nucleotide sequences at the intron/exon junctions of ﬁve analyzed genes.
Putative BPS is underlined. PPT is shown by a bracket. Mutant nucleotides are indicated at E
+1.( B) RT–PCR of minigenes expressed in HEK293
cells carrying the wild-type (WT) or patient’s (PT) nucleotide. The mutations cause exon skipping in GH1, FECH and EYA1, but not in LPL and
HEXA. Mean and SD of three independent experiments of the densitometric ratios of the exon-skipped product is shown at the bottom.
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35-siRNA had no effect on the expression
level of U2AF
65. As expected, the down-regulation of
U2AF
35 increased exon skipping of GH1 and FECH
(Figure 2B) but not to the levels of the mutant constructs
(Figure 1B). Again, as expected, we observed no effect on
LPL and HEXA. Unexpectedly, however, EYA1
demonstrated no response to the down-regulation of
U2AF
35. Less efﬁcient effects of U2AF
35-siRNA on
GH1, FECH and EYA1 (Figure 2B) compared to the
mutant constructs (Figure 1B) were likely because the
mutation abolished binding of U2AF
35 in all the cells,
whereas substantial numbers of cells failed to incorporate
U2AF
35-siRNA and gave rise to normally spliced
products.
We additionally introduced the siRNA-resistant
p3XFLAG-U2AF
35 to ensure that the effect of
siRNA-U2AF
35 was not due to off-target effects
(Figure 2C). As expected, coexpression of p3XFLAG-
U2AF
35 partially rescued the splicing defects in GH1
and FECH (Figure 2D).
U2AF
35 is required for binding of U2AF
65 to PPT in
FECH but not in LPL
To further prove that U2AF
35 is required for pre-mRNA
splicing, we employed an electrophoretic mobility shift
assay (EMSA) using wild-type and mutant RNA sub-
strates of FECH and LPL (Figure 3A). His-tagged
U2AF
35 and U2AF
65 were expressed using bacluovirus
and were puriﬁed under denatured and native conditions,
respectively. Denatured U2AF
35 was refolded before
RNA-EMSA. As expected, U2AF
65 failed to bind to the
wild-type FECH in the absence of U2AF
35, and addition
A
B
C
D
Figure 2. Effects of down-regulation of U2AF
35 on pre-mRNA splicing. (A) Western blots demonstrating that U2AF
35-siRNA efﬁciently knocks
down U2AF
35 but not U2AF
65 or PTBP1. (B) Down-regulation of U2AF
35 facilitates exon skipping in wild-type GH1 and FECH, but not in
wild-type EYA1, LPL and HEXA.( C) Introduction of an siRNA-resistant p3XFLAG-U2AF
35 encoding 3  FLAG fused with U2AF
35 is visualized
by immunoblots against FLAG and U2AF
35.( D) Exon skipping facilitated by U2AF
35-siRNA is partially rescued by introduction of the
siRNA-resistant p3XFLAG-U2AF
35.
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35 gained its binding. For the mutant FECH,
neither U2AF
65 alone nor addition of both U2AFs
showed binding of U2AFs. On the other hand, the
wild-type LPL did not require U2AF
35 to bind to
U2AF
65. Addition of U2AF
35 did not substantially
increased binding of U2AF
65. These bindings were not
affected by the mutation at E
+1 of LPL (Figure 3B).
These results indicate that the mutation in FECH com-
promises a binding afﬁnity for U2AF
35, which in turn
abrogates binding of U2AF
65 and results in aberrant
splicing. On the other hand, wild-type LPL does not
need to bind to U2AF
35 and the mutation at E
+1 has no
effect on the assembly of spliceosome.
PPT determines the splicing consequences of the
mutations
In an effort to delineate effects of the PPT sequences on
the splicing consequence of a mutation at E
+1,w e
introduced a series of mutations into the PPT in the
presence of the mutation at E
+1. Extensions of the
polypyrimidine stretch ameliorated aberrant splicing in
GH1, FECH and EYA1. Conversely, truncations or dis-
ruptions of the polypyrimidine stretch caused exon
skipping in LPL and HEXA (Figure 4).
Length of the polypyrimidine stretch best predicts the
splicing consequences
We next sought for parameters that differentiate normal
and aberrant splicings in these minigenes. Analysis of par-
ameters that potentially dictate the strength of the PPT
indicated that the length of pyrimidine stretch, the number
of pyrimidines in 25 or 50nt at the 30-end of an intron
correlated with the ratio of exon skipping with correlation
coefﬁcients of more than 0.6 (Supplementary Table S1).
The number of pyrimidines in 25 or 50nt at the 30-end of
an intron, however, failed to predict splicing consequences
of nine other constructs shown in Figure 6, and is likely to
be overﬁtted parameters unique to the 35 constructs in
Figure 4. Coolidge and colleagues report that (GU)11 in
PPT is partly functional, but we did not observe alterna-
tive purine and pyrimidine residues in our PPTs and did
not quantify effects of alternative nucleotides (10). We
thus took the length of pyrimidine stretch as a best par-
ameter to dictate the strength of the PPT (Figure 5A). The
native GH1, FECH and EYA1 carry a stretch of 6–10
pyrimidines, whereas the native LPL and HEXA harbor
a stretch of 14 and 13 pyrimidines, respectively (arrows in
Figure 5A). For highly degenerate PPTs in the artiﬁcial
constructs, the total number of pyrimidines in a stretch of
25nt at the 30-end of an intron well predicts the ratio of
exon skipping (Figure 5B). These analyses revealed that
the length of the polypyrimidine stretch should be at least
10–15nt to ensure normal splicing even in the presence of
a mutation at E
+1.
Identiﬁcation of effects on pre-mRNA splicing of
nine disease-associated mutations at the ﬁrst
nucleotide of an exon
We next examined other mutations at E
+1 in which
splicing consequences have not been previously analyzed.
We ﬁrst identiﬁed 224 mutations that abrogate the ﬁrst
‘G’ nucleotide of an exon in the Human Gene Mutation
Database at http://www.hgmd.cf.ac.uk/ (data not shown).
Among these, we arbitrarily chose nine mutations causing
A
B
Figure 3. RNA-EMSA. (A) Sequences of wild-type (WT) and mutant (PT) RNA probes of FECH and LPL employed for RNA-EMSA.
(B) RNA-EMSA of wild-type and mutant FECH and LPL with increasing amounts of U2AF
65 with or without U2AF
35. His-tagged U2AF
65
and U2AF
35 are expressed in Sf9 cells and are puriﬁed. Wild-type FECH requires U2AF
35 to bind to U2AF
65, whereas wild-type LPL does not
require U2AF
35. A mutation at E
+1 abrogates binding of U2AF
65 in FECH but not in LPL. Concentrations of U2AF
35 are 5, 10 and 20ng/ml; and
those of U2AF
65 are 10, 20 and 40ng/ml. Numbers at the bottom indicate intensities of the retarded fragments in arbitrary units.
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6A).
We constructed nine pairs of wild-type and mutant
minigenes, and introduced them into HEK293 cells. We
observed aberrant splicing in PKHD1, COL1A2 (exon 37),
CLCN2, CAPN3 (exons 10 and 17), but not in LAMA2,
NEU1, COL6A2 and COL1A2 (exon 23) (Figure 6B). The
lengths of the polypyrimidine stretch of the ﬁve aberrantly
spliced constructs ranged from 4 to 10nt, whereas those of
the four normally spliced constructs ranged from 9 to
16nt. These results are in concordance with a notion
that the short polypyrimidine stretches are predisposed
to aberrant splicing due to a mutation at E
+1, whereas
long polypyrimidine stretches are tolerant to such muta-
tions. Among the 224 mutations affecting ‘G’ at E
+1, only
three mutations have been reported to cause aberrant
splicing. We here analyzed nine mutations and identiﬁed
ﬁve more such mutations. It is thus likely that most
splicing mutations at E
+1 still remain unrecognized to
date.
Analysis of the 30-splice sites of the human genome
We next analyzed PPTs of 176 809 introns of the entire
human genome. The length of the pyrimidine stretch was
shorter when E
+1 was the conserved ‘G’ (Figure 7A). This
also supports a notion that AG-dependent 30 ss harboring
Ga tE
+1 has a short polypyrimidine stretch (12). In
addition, the ratio of ‘C’ at intronic position  3 was
lower when E
+1 was the conserved ‘G’ (Figure 7B),
which suggests that G at E
+1 makes C at  3 dispensable
for binding to U2AF
35, although this is not directly
relevant to the length of the PPT.
Being prompted by a previous report that U2AF
35
binds up to the 10th nucleotide of an exon (12), we
examined nucleotide frequencies at exonic positions +1
Figure 4. RT–PCR of HEK293 cells transfected with minigenes
carrying artiﬁcially extended or disrupted PPT’s. All the constructs
harbor a mutation at E
+1. The top construct of each gene represents
the patient’s sequence. Only the nucleotide sequences of the 30-end of
an intron are indicated. The longest stretches of the polypyrimidines are
shown in bold. Underlines indicate putative BPS’s. The rightmost
column shows the mean and SD of three independent experiments of
the densitometric ratios of the exon-skipped product.
A
B
Figure 5. Ratios of exon skipping are plotted against the lengths of the
polypyrimidine stretch (A) and the numbers of pyrimidines in 25nt at
the 30-end of an intron (B). The ordinate (percent skipped) represents
the ratios of exon skipping compared to that of the wild-type construct.
The data are obtained from RT–PCR shown in Figure 4. Arrows
indicate the original constructs carrying the patient’s sequence, and
the others are artiﬁcial constructs. Six constructs indicated by ovals
in (A) are plotted in (B).
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the human genome annotation NCBI Build 37.1 (hg19).
As expected, ‘GT’ dinucleotide was frequently observed at
exonic positions+1 and+2. We also observed preference
for a ‘T’ nucleotide at positions +3 to +5 (Figure 7C).
Alignment of SELEX results of U2AF
35 by Wu and col-
leagues (12) similarly demonstrate overrepresentation of
‘T’ nucleotides at positions +3 to +6 (Figure 7D). We
thus analyzed effects of ‘TTT’ at positions +3 to +5
using the GH1, FECH and EYA1 minigenes carrying the
patient’s mutations. We found that introduction of ‘TTT’
at exonic position +3 to +5 had no effect in GH1 and
FECH, but slightly enhanced exon recognition in EYA1
(Figure 7E).
DISCUSSION
We previously reported that the SD-score algorithm efﬁ-
ciently predicts splicing consequences of a mutation affect-
ing the 50 ss (32). We next identiﬁed that the human BPS
consensus is simply yUnAy (5), and hoped to predict if a
given mutation affecting the BPS causes aberrant splicing
or not. The high degeneracy of the BPS consensus,
however, prevented us from constructing an efﬁcient algo-
rithm. In this communication, we worked on mutations at
E
+1. As far as we know, only three such mutations have
been reported to cause aberrant splicing, and only
two such mutations have been reported not to affect
splicing. Knockdown and RNA-EMSA of U2AF
35,a s
well as analyses of artiﬁcial PPT mutations and nine
disease-causing mutations at E
+1 revealed that
AG-dependence of 30 ss determines the splicing conse-
quences. In the presence of a mutation at E
+1, a stretch
of 15 or more pyrimidines ensures normal splicing,
whereas a stretch of 10 or less pyrimidines are predisposed
to aberrant splicing.
AG-dependent 30 ss requires both U2AF
65 and U2AF
35
to bring U2snRNP to the branch point, whereas
AG-independent 30 ss has a long stretch of pyrimidines
that can bind to U2AF
65 without U2AF
35 (13,15).
U2AF
35 potentially provides an additional RNA–protein
interacting force and an additional SR protein-binding
surfaces (33). An artiﬁcial G-to-C mutation at E
+1 down-
stream of a stretch of ﬁve pyrimidines in the mouse IgM
gene abrogates binding of U2AF
35 and causes defective
splicing (14). Similarly, in INSR exon 11 carrying an ‘A’
nucleotide at E
+1, a stretch of 14 pyrimidines but not of 10
pyrimidines is properly spliced (34). Additionally, a
stretch of eight pyrimidines upstream of the last exon
with ‘C’ at E
+1 of EIF3S7 is dependent on U2AF
35,
whereas a stretch of 14 pyrimidines upstream of the last
exon with ‘A’ at E
+1 of CUEDC1 is independent (15). Our
observations and previous reports all point to a notion
that effects on pre-mRNA splicing should be scrutinized
for a mutation at E
+1 if the preceding intron carries a
short stretch of 10 or less pyrimidines. Indeed, in our
analysis of nine disease-causing mutations, ﬁve of six
mutants with 10 or less contiguous pyrimidines were ab-
errantly spliced (Figure 6), but no splicing analysis has
been documented for any of them.
A
B
Figure 6. RT–PCR analysis of nine disease-causing mutations at E
+1.( A) Sequences at the intron/exon junctions of nine pairs of wild-type and
mutant constructs. The longest polypyrimidine stretches are underlined. (B) RT–PCR of minigenes transfected into HEK293 cells. Five mutant
constructs are aberrantly spliced, whereas the remaining four mutants are normally spliced. Numbers in the parentheses indicate exon numbers. In
PKHD1, a cryptic 30-splice site (open arrowhead in panel A) at 55nt upstream of the native site is activated (asterisk). Mean and SD of three
independent experiments of the densitometric ratios of the exon-skipped product is shown at the bottom.
4402 Nucleic Acids Research, 2011,Vol.39, No. 10We ﬁrst report overrepresentation of ‘T’ nucleotides at
exonic positions+3 to+5 in the human genome, as well as
in in vitro U2AF
35-binding sites. Enhancement of exon
recognition in EYA1 by introduction of ‘TTT’ at positions
+3 to+5 also underscores a notion that ‘TTT’ at+3 to+5
is likely to enhance binding of U2AF
35. Effects of ‘TTT’,
however, were not observed in GH1 and FECH. As the
patient’s mutation in GH1 and FECH resulted in almost
complete skipping of an exon, whereas that in EYA1 gave
rise to both exon-skipped and included products. The
degrees of aberration of exon recognition may account
for the ‘TTT’-responsiveness. Alternatively, although no
ESE motif was detected in the ‘TTT’-introduced EYA1 by
ﬁve different ESE search tools, an unrecognized ESE
might have ameliorated exon skipping in EYA1. Further
analysis is required to elucidate effects of overrepre-
sentation of ‘T’ at positions+3 to+5.
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